Skip to main content
Log in

The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The objectives of this study were to establish if, and to what extent, benzbromarone affects allopurinol/oxypurinol kinetics, and to compare the uric acid lowering capabilities of Allomaron® (allopurinol 100 mg plus benzbromarone 20 mg) with the effects of allopurinol alone in patients with confirmed gout.

We studied 14 adult men in an open randomized cross-over study. After a 14 day run-in period with Zyloprim® (2×100 mg allopurinol tablets in the morning), the patients were randomly allocated to morning doses of either Allomaron® (2 tablets) or Zyloprim® (2 tablets). Seven days later cross-over was effected and the alternative treatment was taken for a further 7 days.

On days 7 and 14 the patients came into hospital and venous blood samples were taken over 24 h for allopurinol and oxypurinol assays by HPLC. Serum uric acid was determined on days -14, 1, 7, and 14.

Benzbromarone lowered plasma oxypurinol concentrations (Allomaron®/Zyloprim® mean ratio of AUC0→24 was 59%; 95% confidence interval 54–64%), but did not affect plasma allopurinol concentrations.

Despite this pharmacokinetic interaction of benzbromarone with allopurinol, resulting in lower plasma concentrations of oxypurinol, Allomaron® was superior to allopurinol alone in lowering serum uric acid, probably because of the added uricosuric effect of benzbromarone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Arntz HR, Dreykluft HR, Leonhardt H (1979) Wirkung Harnsäuresenkender Medikamente in niedriger Dosierung. Fortschr Med 97: 1212–1214

    Google Scholar 

  • Breithaupt H, Tittel M (1982) Kinetics of allopurinol after single intravenous and oral doses: noninteraction with benzbromarone and hydrochlorothiazide. Eur J Clin Pharmacol 22: 77–84

    Google Scholar 

  • Elion GB, Kovensky A, Hitchings GH, Metz E, Rundles RW (1966) Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 15: 863–880

    Google Scholar 

  • Elion GB, Yü T-F, Gutman AB, Hitchings GH (1968) Renal clearance of oxypurinol, the chief metabolite of allopurinol. Am J Med 45: 69–77

    Google Scholar 

  • Gardner MJ, Altman DG (1986) Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J 292: 746–750

    Google Scholar 

  • Hande K, Reed E, Chabner B (1978) Allopurinol kinetics. Clin Pharmacol Ther 23: 598–605

    Google Scholar 

  • Löffler W, Gröbner W (1982) Kombinierte Behandlung der Hyperurikämie. In: Zöllner N (Hrsg) Hyperurikämie und Gicht 5. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Matzkies F, Berg G (1976) Behandlung der Hyperurikämie mit einer Kombination von Allopurinol und Benzbromaron. Dtsch Med Wochenschr 101: 1568–1570

    Google Scholar 

  • Mertz DP (1976) Vermindertes Risiko bei der Behandlung von Gicht und Hyperurikämie. Dtsch Med Wochenschr 101: 1288–1292

    Google Scholar 

  • Mertz DP (1977) Gicht — Neuere Ergebnisse zur Pathogenese, Diagnose und Therapie. Hippokrates 48: 340–350

    Google Scholar 

  • Mertz DP, Loewer H (1979) Wirkungsprofil der Harnsäuresenkung bei Höherdosierung von Allopurinol. Dtsch Med Wochenschr 104: 324–325

    Google Scholar 

  • Steinijans VW, Diletti E (1983) Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 24: 127–136

    Google Scholar 

  • Walter-Sack J, Gröbner W, Zöllner N (1979) Verlauf der Oxipurinol-Spiegel im Plasma nach akuter und chronischer Gabe von Allopurinol in verschiedenen galenischen Zubereitungen. Arzneimittelforschung (Drug Res) 29: 839–842

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müller, F.O., Schall, R., Groenewoud, G. et al. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin Pharmacol 44, 69–72 (1993). https://doi.org/10.1007/BF00315283

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315283

Key words

Navigation